Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

CymaBay Following The Leaders, Pursues NASH, PBC Simultaneously

Apr 16 2019

• By Joseph Haas

Sujal Shah of CymaBay Pharmaceuticals. — CymaBay CEO Sujal Shah

Related Content

Genfit Hopes To Make Case For First-Line Treatment In NASH

Apr 04 2019

Intercept's OCA Data Bolster NASH Efficacy, But Pruritus Worries Worsen

Apr 11 2019

NASH Pipeline: Racing To The Finish

Mar 21 2019

Intercept Makes No Changes To Ocaliva NASH Study Despite PBC Safety Issues

Sep 25 2017

Related Companies

CymaBay Therapeutics, Inc.

Intercept Pharmaceuticals, Inc.

Genfit SA

Madrigal Pharmaceuticals, Inc.

Additional Topics

Business Strategies Commercial Clinical Trials Companies Liver & Hepatic BioPharmaceutical

More from Alimentary/Metabolic

More from Therapy Areas

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window